CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway

Dan Wu a,1, Xinyi Guo b,1, Jing Su a, Ruoying Chen a, Dmitriy Berenzon c, Martin Guthold b, Keith Bonin b, Weiling Zhao a, Xiaobo Zhou a,⁎

⁎ Corresponding author at: Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

A B S T R A C T

As the second most prevalent hematologic malignancy, multiple myeloma (MM) remains incurable and relapses due to intrinsic or acquired drug resistance. Therefore, new therapeutic strategies that target molecular mechanisms responsible for drug resistance are attractive. Interactions of tumor cells with their surrounding microenvironment impact tumor initiation, progression and metastasis, as well as patient prognosis. This cross-talk is bidirectional. Tumor cells can also attract or activate tumor-associated stromal cells by releasing cytokines to facilitate their growth, invasion and metastasis. The effect of myeloma cells on bone marrow stromal cells (BMSCs) has not been well studied. In our study, we found that higher stiffness of BMSCs was not a unique characteristic of MM patients (M-BMSCs). BMSCs from MGUS (monoclonal gammopathy of undetermined significance) patients were also stiffer than the BMSCs from healthy volunteers (N-BMSCs). The stiffness of M-BMSCs was enhanced when cocultured with myeloma cells. In contrast, no changes were seen in myeloma cell-directed cross-talk with BMSCs and reveal that CD138-negative myeloma cells are crucial for MM pathogenesis. Myeloma cells adhere to BMSC or ECM proteins, such as fibronectin, collagen, laminin and osteopontin, and the liquid milieu including cytokines, growth factors and chemokines. Interaction of myeloma cells with bone marrow microenvironments is crucial for MM pathogenesis. Myeloma cells adhere to BMSC or ECM not only for bone marrow homing, but also for activation of pleiotropic proliferative and anti-apoptotic cascades [9]. Adhesion of myeloma cells

1. Introduction

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow. It accounts for 10% of all malignant hematological diseases [1]. According to the National Cancer Institute cancer statistics, 24,050 new cancer cases of MM will be diagnosed in the United States in 2014, and an estimated 11,090 deaths will occur [2]. In almost all of cases, MM is preceded by a premalignant disease called monoclonal gammopathy of undetermined significance (MGUS) [3,4]. MGUS affects 2% of the population above the age of 50 and progresses to overt MM at a rate of 1% per year [5]. Although discovery of novel therapeutics by targeting important disease-driving pathways has led to significant improvement in MM response and survival of patients, MM remains incurable due to relapse and drug resistance [6,7]. Therefore, understanding the mechanisms associated with MM pathogenesis is necessary for the development of novel targeting agents.

Growing evidence supports the hypothesis that cross-talk between myeloma cells and the bone marrow microenvironment plays an important role in myeloma cell growth and drug resistance [8]. The bone marrow niche includes cellular and noncellular compartments. The cellular compartments are composed of hematopoietic stem and progenitor cells, immune cells, erythrocytes, bone marrow stromal cells (BMSCs), endothelial cells, osteoclasts and osteoblasts. The noncellular compartments consist of various extracellular matrix (ECM) proteins, such as fibronectin, collagen, laminin and osteopontin, and the liquid milieu including cytokines, growth factors and chemokines. Interaction of myeloma cells with bone marrow microenvironments is crucial for MM pathogenesis. Myeloma cells adhere to BMSC or ECM not only for bone marrow homing, but also for activation of pleiotropic proliferative and anti-apoptotic cascades [9]. Adhesion of myeloma cells
to BMSCs triggers NF-κB activation, initiates Notch signaling, and induces secretion of interleukin-6, vascular endothelial growth factor, insulin-like growth factor, and other factors [6,10,11], which have been associated with chemoresistance of MM [12–14]. Our understanding of the contribution of the bone marrow microenvironment on cancer progression is still limited, that’s why elucidating the role of the microenvironment is a major step in improving treatment of MM.

Cancer initiating cells are capable of continuous self-renewal and differentiation into mature cancer cells, and are predicted to be involved in drug resistance. CD138− myeloma cells have been considered as myeloma initiating cells. Matsui et al. first described CD138 negative (CD138−) population with greater clonogenic potential than CD138 positive (CD138+) myeloma cells [15,16]. CD138− clonotypic B cells are also found in the peripheral blood and bone marrow of patients with MM [16,17] and are associated with poor survival of MM patients [18]. Indeed, successful engraftment of CD138− subpopulation from MM patients, but not CD138+, in NOD/SCID mice suggested that CD138− myeloma cells were the principal myeloma initiating cells [19]. CD138− myeloma cells express higher levels of aldehyde dehydrogenase [15,20] and are resistant to anti-MM drugs, such as lenalidomide [15,21].

Microenvironment stiffness plays a crucial role in cancer development and progression. In vitro studies indicate that the mechanical properties of the extracellular matrix have a great impact on cancer growth and differentiation [22–24]. The mechanical integrity of cells is regulated by a dynamic network of structural, cross-linking, and signaling molecules. A previous study reported that BMSCs collected from MM patients were stiffer than healthy BMSCs [25]. The interaction between BMSCs and myeloma stem cells has not been well studied. Feng et al. found that myeloma BMSCs stimulated growth and survival of myeloma initiating cells in vitro and in vivo, which was partially mediated via the SDF-1/CXCR4 signaling pathway [26]. Tumors have the ability to shape microenvironment by secreting growth factors, cytokines and chemokines to meet their needs for development. In this study, we determined the effect of myeloma cells on the stiffness of BMSCs and explored the molecular mechanisms underlying these mechanical changes. We found that BMSCs from MM (M-BMSC) and MGUS (MGUS-BMSC) patients were stiffer than normal BMSCs (N-BMSCs). The stiffness of M-BMSCs was enhanced when cocultured with myeloma cells. However, no changes were seen in the stiffness of myeloma cell-primed MGUS− and N-BMSCs. CD138− myeloma cells, but not CD138+ cells, mediated the stiffness of M-BMSCs. SDF-1 was highly expressed in CD138− myeloma cells compared with that in CD138+ cells. Inhibition of SDF-1 by a pharmacological inhibitor AMD3100 or knocking-down CXCR4 using siRNA abolished CD138− myeloma cells-induced increase in M-BMSC stiffness, suggesting a key role of SDF-1. Effects of SDF-1 on M-BMSC stiffness appear to be mediated by AKT.

2. Materials and methods

2.1. Isolation and expansion of BMSCs

Primary human BMSCs were derived from identified human whole bone marrow aspirates. Usage of these samples has been approved by the Institutional Review Board of The Methodist Hospital Research Institute (TMHRI) and Wake Forest University Health Science (WFUHS). BMSC isolation was conducted as previously described [26]. Bone marrow mononuclear cells were obtained by Ficoll density gradient (1.077 g/ml; Sigma, St. Louis, MO) and then plated into 35 cm2 tissue culture. The cells at fourth passages were cryopreserved in a liquid nitrogen tank and stored for subsequent experiments. The human marrow stromal cell lines H5S, derived from the marrow of a healthy volunteer were obtained from ATCC.

2.2. Atomic force microscope (AFM) assay

All cell stiffness measurements were performed using a combined atomic force microscope (AFM)/inverted optical microscope [27–29] at room temperature. The AFM (Topometrix Explorer, Veeco Instruments, Woodbury, NY) was situated above the sample and fit on a custom-designed stage of the inverted optical microscope (Axiovert 200, Zeiss, Thornwood, NY, USA). The optical microscope was equipped with a high sensitivity emCCD camera (EM-CCD C9100-02, Hamamatsu Photonics KK, Japan) and iPLab imaging software (Scanalytics, Fairfax, VA). The stage was designed so that the samples could be moved in the x- and y-directions independently when the AFM was sitting on the stage. We used tip-less AFM silicon probes (Applied Nano Structures Inc., USA) to which we attached 5.3 μm fluorescent melanine beads (Microspheres–Nanospheres, Cold Spring, NY). The AFM probes had nominal spring constants of k = 0.1–0.6 N/m, length L = 225 μm, and width, w = 43 μm. A more accurate spring constant was determined from the dimensions and the resonance frequency of the AFM probe, and our probes were calibrated against known gel standards, as described in more detail in [30]. The approach and retraction speeds were 1 μm/s, with an indentation depth of 1.5 μm. Thus, the frequency was (1 μm/s) / (2 × 1.5 μm) = 0.33 Hz. This frequency is a good, commonly used compromise between two opposing requirements for cell measurements. On the one hand it is slow enough to minimize viscous components, on the other hand is it fast enough to provide stable measurements on cells. Importantly, it is also slower than the typical speed with which cells move or change.

For each sample, 30–60 indentation measurements were collected over a period of 2 h. The number of cells for our measurement series is sufficiently large according to the standards of the AFM community [31]. All measurements were carried out in Mesencult basal medium. Data processing was done as described in previously published work [30].

2.3. CD138− myeloma cell isolation

NCI H929 human myeloma cells were obtained from ATCC and CD138−/CD138+ subpopulation was separated by a MACS separator, according to the manufacturer’s instructions. CD138 microbeads, MACS Columns and MACS Separators were purchased from Miltenyi Biotec (Auburn, California). NCI H929 cells were suspended in 80 μl 0.5% MACS buffer and incubated with 20 μl of CD138 microbeads for 15 min at 4 °C. Place an MS column into the separator magnet. After wash, the cells were then resuspended in 500 μl MACS buffer and loaded onto MS MACS column. The magnetic labeled CD138− cells were bound to the column. The effluent containing non-labeled CD138+ cells were collected in a 1.5 ml tube. The magnetic labeled CD138− cells were then released from magnetic field using 1 ml wash buffer.

2.4. Western blotting

Cells were lysed using RIPA buffer supplemented with protease and phosphatase inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and stored in aliquots at −20 °C until use. Twenty micrograms of cell lysates was mixed with an equal volume of Laemmli sample buffer, denatured by boiling, and separated by SDS-PAGE. The separated proteins were then transferred to a nitrocellulose membrane (BioRad). The membranes were blocked using 5% non-fat dry milk for 1 h at room temperature and probed with anti-phospho-Akt (Ser473) rabbit mAb (Cell signaling, Beverly, MA), anti-phospho-RhoA (Ser188) rabbit mAb (Cell signaling), anti-phospho-Myosin light chain (Ser19) rabbit mAb (Cell signaling), anti-phospho-FAK (Tyr925) rabbit mAb (Cell...
signaling), anti-Akt rabbit mAb (Cell signaling), and anti-phospho-CXCR4 (Ser339) rabbit mAb (Sigma-Aldrich, St. Louis, MO). After washing three times in TBST, the blots were incubated with IgG horseradish peroxidase conjugated anti-rabbit antibody (Cell signaling, Beverly, MA) at a final concentration of 1:5000 for 2 h at room temperature. Immunoblots were developed using the enhanced chemiluminescence (ECL) reagent (Cell signaling, Beverly, MA) and visualized using FluroChemQ processor (Proteinsimple, Santa Clara, CA).

2.5. RNA extraction and Real-time quantitative PCR

Total RNA was extracted using an RNeasy Micro kit (Qiagen, Santa Clarita, CA) according to the manufacturer’s instructions. First-strand cDNA was synthesized using superscript III first-strand synthesis system (Invitrogen) according to the recommendations of the manufacturer. Briefly, 1 μg of total RNA, 0.5 μg of oligo dT and nuclear-free water were heated at 65 °C for 10 min and then chilled on ice for 5 min. Forty units of RNase inhibitor (Promega, Madison, WI), 3 μl of 100 mM DTT (GIBCO), 1 μl of 10 mg/ml bovine serum, 6 μl of 5× first-strand synthesis buffer, 2 μl of nuclear-free water, and 200 U superscript III reverse transcriptase were then added together and mixed well. The mixture was incubated at 50 °C for 50 min and at 85 °C for 10 min. Then the mixture was chilled on ice and incubated with RNase H at 37 °C for 20 min. Synthesized cDNA could be stored at −20 °C until use.

Quantitative real time PCR (qPCR) reactions were carried out on the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City, CA). SDF-1 and β-actin SYBR based primers were obtained from RealTimePrimers (Elkins Park, PA). Briefly, 20 μl of reaction mixture was mixed with a 10 μl Power SYBR green PCR master mix (Invitrogen), 80 ng of cDNA, 300 nM of upstream and downstream primers and nuclear-free water. PCR reaction was conducted with 1 cycle at 95 °C for 10 min, 40 cycles at 95 °C for 15 s, 40 °C for 30 s and 60 °C for 1 min, followed by dissociation curve analysis distinguishing PCR

Fig. 1. Detect stiffness of BMSCs from MM, MGUS patients and normal volunteers using AFM (atomic force microscopy). A: schematic diagram showing detection of stiffness in a single cell using AFM. B: A representative fluorescence microscopy image (40× objective lens) showing an AFM cantilever (width 43 μm) with a fluorescent bead (5.3 μm diameter) approaching a cell. C: The stiffness of BMSCs collected from MM, MGUS and healthy volunteers was determined by AFM and expressed as Young’s moduli. Data was collected from 60 cells of M-BMSCs, 43 MGUS-BMSCs and 47 N-BMSCs. D: BMSCs were co-cultured with NCI H929 myeloma cells for 24 h. The stiffness of BMSCs was measured after removing NCI H929 cells. Data was calculated from 52 cells of M-BMSCs, 30 MGUS-BMSCs and 57 N-BMSCs. All experiments were repeated 3 times. Mean ± SE; **p < 0.01.
products. The average ΔΔCT and standard deviation were determined from three independent experiments.

2.6. Coculture of BMSCs and myeloma cells

BMSCs at passage 3–6 were cultured in 35 mm dishes. When BMSCs reached 40%–60% confluence, NCI H929 cells were then added into the same culture dish and incubated for 24 h. After washing several times with PBS to remove NCI H929 cells, BMSCs were ready for AFM analysis.

2.7. Statistical analysis

Statistical analysis was carried out using a Student’s t-test to discern differences of the data when appropriate. p values less than 0.05 were considered statistically significant.

3. Results

3.1. Myeloma cells modulate biomechanical properties of M-BMSCs

AFM is a reliable way to measure stiffness of living cells. One of its unique advantages is that it records micro-scale stiffness on individual cells, layers of cells or even on pieces of tissue [32]. A brief description of the AFM procedures is summarized in Fig. 1. Cells were indented 1000 nm with a spherical AFM probe. Cell stiffness (Young’s modulus) was determined by fitting a Hertz model of a hard sphere indenting a soft, elastic surface to the data [30]. 30–60 single cells were detected for each condition. As shown in Fig. 1C, the mean stiffness of N-BMSCs, MGUS-BMSCs and M-BMSCs was 670 ± 20 Pa, 1360 ± 100 Pa and 1550 ± 100 Pa, respectively. The values quoted here were mean Young’s moduli ± SEM. Our data indicated that MGUS and M-BMSCs are stiffer than N-BMSCs. No significant difference was observed between N-BMSCs and MGUS-BMSCs. Since myeloma cells always attached to BMSCs, we tested the stiffness of BMSCs after co-culturing them with NIH 9292 myeloma cells for 24 h. There was no change in the stiffness of N-BMSCs (770 ± 40 Pa). The stiffness of M-BMSCs was significantly increased (2140 ± 180 Pa). There was a slight decrease in the stiffness of MGUS-BMSCs (960 ± 110 Pa); however this was not statistically significant (Fig. 1D). Our results indicated that myeloma cells were able to modify the biomechanical properties of BMSCs.

3.2. CD138− myeloma cells, but not CD138+ cells, regulated M-BMSC stiffness

The cancer stem cell hypothesis postulates that only a small subpopulation of cells can initiate a tumor or cause a tumor relapse [33]. CD138− myeloma cells have been considered as myeloma initiating cells [15,34]. Since we found the myeloma cells induced biomechanical changes in M-BMSCs, the effect of CD138− myeloma cells on the biomechanical architecture of M-BMSCs is unknown. To test the effect of myeloma initiating cells on M-BMSC stiffness, we separated NCI H929 MM cells into CD138− and CD138+ subpopulations. The stiffness of M-BMSCs was detected after coculturing with CD138− or CD138+ cells. A significant increase in the stiffness (57.6%) of M-BMSCs was noted when co-cultured with CD138+ cells compared with that determined in the non-cocultured M-BMSCs. No change in the stiffness of M-BMSCs was observed after co-culturing with CD138− cells (1290 ± 9 Pa) as shown in Fig. 2A. Our data suggested that CD138+ cells played a key role in myeloma cells-mediated biomechanical changes of M-BMSCs.

3.3. SDF-1/CXCR4 signaling was essential for the CD138− myeloma cells-enhanced stiffness of M-BMSCs

Earlier studies have shown that SDF-1 and its receptor CXCR4 are critical regulators of the interaction between MM cells and BMSCs [35]. To investigate if SDF-1/CXCR4 regulated the interaction between CD138− cells and BMSCs, we first compared the expression of SDF-1 in CD138− and CD138+ myeloma subpopulations. SDF-1 mRNA levels were determined using qPCR. As shown in Fig. 2B, SDF-1 was highly expressed in CD138+ myeloma cells compared to that in the CD138− cell subpopulation. To determine the direct effect of SDF-1 on BMSC stiffness, N-BMSCs, MGUS-BMSCs and M-BMSCs were treated with 100 ng/ml recombinant SDF-1 for 2 h and then their moduli were measured using AFM. Treating M-BMSCs with SDF-1 led to a ~50% increase (from 1550 ± 70 Pa to 2050 ± 90 Pa) in the stiffness of cells. In contrast, the stiffness of N-BMSCs and MGUS-BMSCs remained unchanged (Fig. 3A). AMD3100 is a specific CXCR4 antagonist. Western blot
Fig. 3. CD138⁻ myeloma cell-enhanced stiffness of M-BMSCs was regulated by SDF/CXCR4 signaling. A: Stiffness in M-BMSCs, MGUS-BMSCs and N-BMSCs after incubation for 2 h w/wo 100 ng/ml SDF-1. Data was calculated from 35 cells of M-BMSCs, 43 MGUS-BMSCs and 61 N-BMSCs. B: Representative Western blots showing the protein level of p-CXCR4 in AMD3100-treated and untreated M-BMSCs. C: Stiffness in M-BMSCs treated with 250 μg/ml AMD3100 and/or 100 ng/ml of SDF-1. Data was calculated from 35 cells of M-BMSCs, 30 SDF-1 treated M-BMSCs, 35 AMD3100 treated M-BMSCs, and 30 AMD3100 and SDF-1 treated M-BMSCs. D: Western blots and qPCR showing the protein level (upper panel) and gene expression (lower panel) of CXCR4 in M-BMSCs transiently transfected with CXCR4 or non-targeted scrambled RNAi. E: Stiffness in M-BMSCs that were transiently transfected with CXCR4 or scrambled RNAi and then treated with SDF-1. Data was calculated from 35 cells of M-BMSCs, 30 SDF-1 treated M-BMSCs, 30 scramble treated M-BMSCs, 30 CXCR4 RNAi treated M-BMSCs and 30 CXCR4 RNAi-SDF-1 treated M-BMSCs. F: Stiffness in M-BMSCs that preincubated AMD3100 and then cocultured with CD138⁻ myeloma cells. Data was calculated from 35 cells of M-BMSCs, 30 CD138⁻ cells primed M-BMSCs, 30 AMD3100 treated M-BMSCs, and 30 AMD3100-CD138⁻ cells treated M-BMSCs. G: Stiffness in M-BMSCs that cocultured with CD138⁻ cells and CD138⁺ cells transfected with CXCR4 or scrambled RNAi. Data was calculated from 35 cells of M-BMSCs, 30 CD138⁺ cells primed M-BMSCs, 30 scramble-CD138⁻ cells primed M-BMSCs, and 30 CXCR4 RNAi-CD138⁺ cells treated M-BMSCs. All experiments were repeated 3 times. Mean ± SE; **p < 0.01.
analysis showed that treating M-BMSCs with 250 μg/ml of AMD3100 inhibited CXCR4 phosphorylation (Fig. 3B). To determine if inhibition of CXCR4 affected SDF-1-elevated stiffness of M-BMSCs, M-BMSCs were incubated with AMD 3100 for 22 h and then treated with 100 ng/ml of SDF-1 for 2 h. Pretreatment with AMD3100 blocked the SDF-1-induced increase in the stiffness of M-BMSCs (Fig. 3C). To further confirm the role of SDF-1/CXCR-4 in BMSC stiffness, we knocked down CXCR4 expression in M-BMSCs using siRNA. Transient transfection of CXCR4 siRNA led to a >75% reduction in CXCR4 mRNA level (Fig. 3D). AFM analysis showed that knocking-down CXCR4 abolished SDF-1-induced increase in the stiffness of M-BMSCs (Fig. 3E). To determine the role of SDF1/CXCR4 signaling in CD138− myeloma cell-mediated stiffness of M-BMSCs, M-BMSCs were treated with AMD3100 or transfected with CXCR4 siRNA. Inhibition of SDF-1 by AMD3100 or CXCR4 siRNA blocked CD138− myeloma-induced increase in M-BMSC stiffness (Fig. 3F & G), suggesting that CD138− myeloma cells-enhanced stiffness of M-BMSCs was mediated through SDF-1/CXCR4 signaling.

3.4. Molecular alteration of stiffness-associated proteins in BMSCs following treatment with recombinant SDF-1 protein

To determine if treatment of BMSCs with SDF-1 modulated stiffness-associated proteins, M-BMSCs, MGUS-BMSCs and N-BMSCs were treated with recombinant SDF-1 and cell lysates harvested at 15 and 60 min post-treatment for protein analysis using Western blots. Focal adhesion kinase (FAK), RhoA and myosin light chain 2 (MLC) are proteins associated with cytoskeletal mechanics and cell contraction, which play an
important role in regulating cell stiffness [36–39]. Our data showed that the phosphorylated protein levels of FAK, RhoA, and MLC were unchanged (Fig. 4A, B, C & D) in N-BMSCs and MGUS-BMSCs, but significantly upregulated in M-BMSCs following treatment with SDF-1 (Fig. 4E & F).

3.5. AKT and FAK activation were required for SDF-1-mediated mechanical alteration of M-BMSCs

AKT activation has been linked with SDF-1/CXCR4-mediated tumor cell migration and angiogenesis [40]. We observed a marked increase in p-AKT protein level in M-BMSCs treated with SDF-1 (Fig. 5). Treating M-BMSCs using PI3K/AKT inhibitor LY294002 reduced p-AKT protein level (Fig. 6A). To determine the role of AKT activation in SDF-1-regulated cell stiffness, M-BMSCs were incubated with 50 μM LY294002 for 12 h and then treated with recombinant SDF-1 for 2 h. As shown in Fig. 6B, inhibition of AKT activation eliminated the SDF-1-induced increase in the stiffness of M-BMSCs.

Furthermore, we also detected the role of FAK activation in SDF-1-mediated M-BMSC stiffness. Cells were pre-incubated with 1 μM FAK inhibitor 14 for 12 h and then treated with SDF-1 for 2 h. As shown in Fig. 6C, inhibition of FAK activation abolished the SDF-1-induced increase in the stiffness of M-BMSCs.

4. Discussion

In the current study, we found that BMSCs collected from MM and MGUS patients were stiffer than those collected from healthy individuals. BMSCs from MM patients showed increased stiffness when cocultured with NCI-H929 MM cells, which was not observed in N-BMSCs and MGUS-BMSCs. CD138− myeloma cells, but not CD138+ cells, expressed high level of SDF-1 and regulated M-BMSC stiffness. Inhibition of SDF-1 using a pharmacological inhibitor

Fig. 5. Incubation with SDF-1 led to elevated phosphorylation of AKT in M-BMSCs. A: Representative Western blots showing the protein levels of p-AKT in N-BMSCs at 15 and 60 min post-treatment with 100 ng/ml SDF-1. B: Densitometric quantification of the data showing in A. C: Representative Western blots showing the protein level of p-AKT treated with SDF-1 in MGUS-BMSCs. D: Densitometric quantification of the data showing in C. E: Representative Western blots showing the protein level of p-AKT in M-BMSCs treated with SDF-1. F: Densitometric quantification of the data showing in E. All experiments have been repeated 3 times, Mean ± SE; **p < 0.01.
or knocking-down CXCR4 in M-BMSCs abolished CD138− myeloma cells-induced increase in M-BMSC stiffness, suggesting an important role of SDF-1/CXCR4 signaling.

Interactions of tumor cells with their surrounding microenvironment have been known to impact tumor initiation, progression and metastasis, as well as patient prognosis [41]. The mechanical properties of stroma can govern cellular behavior of tumors through a variety of biochemical and biophysical mechanisms. Using an in vitro system of matrix-coated polyacrylamide gels, Schrader et al. found that increasing matrix stiffness promoted hepatocellular carcinoma cell proliferation [42]. Weaver and Kumar reported that cross-linked ECM collagen increased ECM stiffness and promoted malignancy [43]. Paszek et al. found that matrix stiffness promoted malignant transformation of a tissue [24]. Preclinical studies using mouse models showed that cancer cells were more proliferative and migrative on the stiff microenvironment [44]. Adhesion of MM to BMSCs has been suggested to be crucial for myeloma cell proliferation and drug resistance. BMSC production of matrix proteins and factors such as fibronectin [6], insulin-like growth factor-1 (IGF-1) [7], stromal derived factor 1 alpha (SDF-1) [8], tumor necrosis factor alpha (TNF-α), B cell activating factor family (BAFF), and a proliferation inducing ligand (APRIL) [5] has all been shown to promote MM cell proliferation and resistance to conventional chemotherapeutic agents. Corre et al. reported that BMSCs from MM patients had a distinctive gene expression profile comparing with normal BMSCs [45]. A total of 79 genes in BMSCs from MM patients were overexpressed and 46% of them involved in tumor-microenvironment cross-talk. It has been reported that myeloma BMSCs increase the colony-forming ability, growth and survival of myeloma stem cells as compared with normal BMSCs [26]. Fuhler and his colleagues have proved that increased numbers of CD138− cells and cell–cell adhesion observed upon myeloma cells cultured with BMSCs [46]. BMSC revert myeloma cells to less differentiated phenotype by combined activities of adhesive interactions and IL6, which might contribute to stromal cell-conferring drug resistance [47]. The interaction between the
components of tumor environment and tumor cells is bidirectional. Tumor cells can also attract or activate tumor-associated stromal cells by releasing a number of growth factor, cytokines and chemokines to facilitate their growth, invasion and metastasis [48–50]. An early study reported that BMSCs from MM patients were significantly stiffer than BMSCs obtained from healthy volunteers using a cytocompression device [25]. Our results indicated that higher stiffness of BMSCs was not a unique feature of M-BMSCs. MGUS-BMSCs were also stiffer than N-BMSCs. The stiffness of M-BMSCs was further enhanced when cocultured with myeloma cells.

Though the cancer stem cell is still a debatable concept, CD138− myeloma subpopulation has been recognized as MM initiating cells in several studies [15,34]. Why myeloma is incurable and relapses in multiple myeloma patients is still unknown. One potential mechanism is that myeloma initiating cells or stem cells are capable of escaping from the effects of chemotherapy/radiotherapy and growing into mature myeloma cells. Identifying the communication between myeloma initiating cells and the bone marrow microenvironment might facilitate the development of new strategies to halt progression of the disease. We found that CD138− myeloma cell-primed M-BMSCs became stiffer than non-primed counterparts. No change in the stiffness of M-BMSCs was observed after co-culturing with CD138− cells. These results suggest that CD138− myeloma cells play an important role in regulating biomechanical properties of M-BMSCs. Our studies demonstrated the cross-talk between myeloma initiating cells with BMSCs.

Gene expression profiling analysis shows that mRNA level of SDF-1 is low in both primary myeloma cells and M-BMSCs comparing with that from their healthy counterparts [45,51]. Interestingly, when we analyzed mRNA level of SDF-1 in CD138− and CD138+ MM cells using qPCR, we found that SDF-1 was highly expressed in CD138− cells when compared with that in the CD138+ subpopulation (Fig. 2D). SDF-1 is secreted by bone marrow endothelial cells, BMSCs, immature osteoblasts, primary malignant plasma cells and myeloma cells [52,53] and it is a critical regulator of myeloma cell migration, homing and adhesion to stromal cell [35,54]. Our results showed that SDF-1 regulates the stiffness of M-BMSCs, but not N-BMSCs or MGUS-BMSCs. Inhibition of SDF1 signaling, using either a pharmaceutical inhibitor or knocking-down SDF-1 receptor CXCR4 in M-BMSCs, abolished the CD138− myeloma cell-induced increase in the stiffness of M-BMSCs. This suggests that the SDF-1/CXCR4 signaling pathway is responsible for CD138− myeloma cell-mediated mechanical changes in M-BMSCs. FAK plays an important role in cell adhesion and regulation of cellular mechanical properties. FAK has been reported to increase cell stiffness and contractile force [55]. Rho GTPases are key regulators of cytoskeletal tension that are correlated with increased stress fiber formation, cell stiffness, integrin activation and myosin phosphorylation [56]. MLCK has been shown to promote cell contractility. Cell stiffness is strongly regulated by phosphorylation of MLCK subunit on the Ser19 [57,58]. Therefore, we used FAK, RhoA and MLCK as molecular markers of cell stiffness. Western blotting analysis showed that the phosphorylated protein levels of FAK, RhoA and MLCK were increased in SDF-1− treated M-BMSCs.

The SDF-1/CXCR4 axis has been reported to regulate tumor cell proliferation and migration through activation of several signaling pathways [40,52], including PI3K/AKT. AKT and FAK were specifically activated in the M-BMSCs following treatment with SDF-1, which was not seen in other BMSCs. AKT and FAK are two important kinases to regulated tumor cell adhesion, invasion and migration [59,60]. Blockage of AKT and FAK activity using selective inhibitors abolished SDF-1− induced mechanical changes in M-BMSCs. Our data indicated that both AKT and FAK activation are required for the action of SDF-1 in M-BMSCs.

5. Conclusions

Our studies demonstrate that (1) M-BMSCs and MGUS-BMSCs had increased stiffness compared with N-BMSCs; (2) MM cells enhanced the stiffness of M-BMSCs; (3) CD138− myeloma cells, but not CD138+ cells, upregulated the stiffness of M-BMSCs; (4) CD138− myeloma cell-induced increase in M-BMSC stiffness was mediated by SDF-1/CXCR4 signaling pathways; and (5) AKT and FAK activation was required for SDF-1− enhanced M-BMSC stiffness. To the best of our knowledge, this is the first study to demonstrate myeloma cell-directed tumor-BMSC communication and delineate the role of CD138− myeloma cells and SDF-1 in regulation of M-BMSC stiffness. Further understanding of the mechanism (s)-associated with myeloma initiating cells with their various components of their microenvironment can help us identify new therapeutic targets for treatment of MM.

Financial support

NIH grant U01CA166886 (X.Z.), National Science Foundation Materials and Surface Engineering grant CMMA-1152781 (K.B. and M.G.) and a pilot grant from the Center for Molecular Communication and Signaling at Wake Forest University (U01057).

Acknowledgments

This work was supported by NIH grant U01CA166886 (X.Z.), and a pilot grant from the Center for Molecular Communication and Signaling at Wake Forest University (U01057). This material is based upon the work supported by the National Science Foundation under Grant Number 1106105 (K.B. and M.G.). The authors would like to thank Dr. Glen Marrs, director of the WUF Microscopic Imaging Core Facility, for his assistance in SEM images.

References
